Cube Psytech Enters Into Supply Agreement With Psygen Labs

December 20, 2021

Vancouver, BC – Cube Psytech Inc. (the “Company” or “ CUBE”), a biopharmaceutical and biotechnology company focused on the research and development of functional and psychedelic mushroom technologies for use in natural healthcare products, is announcing a new supply agreement. CUBE has agreed to terms with Psygen Labs Inc. (“Psygen”), a Canadian manufacturer of active pharmaceutical ingredients (APIs), and research chemicals produced to good manufacturing practices (GMP) standards. Psygen has applied for a Health Canada Dealer’s Licence which, if issued, will allow production of restricted drugs.  The agreement secures supply, contingent on issue of a Dealer’s Licence to Psygen, of synthetic psilocybin for CUBE’s research and development, and serves to complement previous agreements to secure high quality extracts of naturally produced psilocybin. With the agreement, Psygen continues to add to their portfolio of research and development customers.

“We are proud to add an excellent supplier to our vendors list.” Says Cube Psytech CEO / Co-Founder Erick Factor’. “Our continued mission to develop innovative high quality products depends on securing the best materials and Psygen is a leader in the field.”

“Psygen understands the challenges obtaining a safe and reliable supply of psychedelic material for clinical research. We intend to be the solution as the leading supplier of psychedelic API’s on the global market.” says Nadia Van der Heyden, Psygen’s Director of Sales and Marketing. “We are happy to have Cube Psytech as a customer and look forward to their research developments in the future”.

The agreement and supply of psilocybin to Cube Psytech will be in compliance with Health Canada guidelines.

On Behalf of The Board of Directors
Erick Factor
Chief Executive Officer

Contact: Erick Factor

Investor Relations:

Forward-Looking Information: This news release contains "forward-looking information" within the meaning of applicable securities laws relating to statements regarding the Company's business, products and future of the Company's business. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned not to place undue reliance on forward-looking information. Such forward-looking statements are subject to risks and uncertainties that may cause actual results, performance and developments to differ materially from those contemplated by these statements depending on, among other things, the risks that the Company's products and plan will vary from those stated in this news release and the Company may not be able to carry out its business plans as expected. Except as required by law, the Company expressly disclaims any obligation and does not intend to update any forward-looking statements or forward-looking information in this news release. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. The statements in this news release are made as of the date of this release

Source: Cube Psytech Corporation

Always do your own research and make your own investment decisions. This is not a solicitation to purchase or sell securities. Psychedelic Finance is not a registered investment advisor and does not purport to provide investment advice, whether implied or otherwise. Psychedelic Finance does not independently verify the accuracy or the truth of the statements or representations made by issuers. This message is meant for information and educational purposes only and Psychedelic Finance does not intend for this information to be used to inform an investment decision.